Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06188689 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of A Clinical Diagnostic Test for CRDS

Study acronym: DIAGNOSE CRDS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 19 to 20v15
  2. Study sites: 18 to 19v14
  3. Primary completion date: Dec 2025 to Dec 2027 Completion date: Mar 2026 to Mar 2028v13 Show 1 more changeShow less
    • Completion date: Mar 2026 to Mar 2028
  4. Study sites: 16 to 18v12
  5. Study sites: 15 to 16 Publications: details revised at 4 of 5 entriesv11 Show 1 more changeShow less
    • Publications: details revised at 4 of 5 entries
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 14 to 15v10
  2. Study sites: 13 to 14v9
  3. Study sites: 11 to 13v8
  4. Study sites: 10 to 11v7
  5. Study sites: 9 to 10v6
  6. Study sites: 8 to 9v5
  7. Study sites: 7 to 8 Publications: details revised at 4 of 5 entriesv4 Show 1 more changeShow less
    • Publications: details revised at 4 of 5 entries
  8. Study sites: 16 to 7 Publications: details revised at 4 of 5 entriesv3 Show 1 more changeShow less
    • Publications: details revised at 4 of 5 entries
  9. Site details revised at 16 of 16 sites Publications: details revised at 4 of 5 entriesv2 Show 1 more changeShow less
    • Publications: details revised at 4 of 5 entries
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Trial Details
NCT Number NCT06188689
Lead Sponsor Population Health Research Institute
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions Calcium Release Deficiency Syndrome (CRDS)
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov